MTST (MetaStat) Total Long-Term Assets: $0.40 Mil (As of Feb. 2018)


What is MetaStat Total Long-Term Assets?

MetaStat MTST Total Long-Term Assets is $0.40 Mil as of Feb. 2018.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. MetaStat's Total Long-Term Assets for the quarter that ended in Feb. 2018 was $0.40 Mil.

MetaStat Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for MetaStat's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Total Long-Term Assets Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.81 0.54 0.46 0.40

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.44 0.44 0.42 0.40

MetaStat Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $0.40 Mil mean?
MetaStat (MTST) has a Total Long-Term Assets of $0.40 Mil as of Feb. 2018. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on MetaStat and its competitors.
Is MetaStat's Total Long-Term Assets too high?
MetaStat's current Total Long-Term Assets is $0.40 Mil.
How does MetaStat's Total Long-Term Assets compare to OBMP and NSPX?
MetaStat's Total Long-Term Assets of $0.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on MetaStat and its competitors. MetaStat's current Total Long-Term Assets is $0.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current Total Long-Term Assets of $0.40 Mil. The current Total Long-Term Assets is $0.40 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For MetaStat (MTST), the current Total Long-Term Assets is $0.40 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.